Charles River to acquire Frontage's bioanalysis and DMPK operations for $470 million
The deal, announced November 9, 2026, adds Exton, Pennsylvania testing sites and could carry up to $75 million more in performance-based payments.
SEC filing
2 stories
The deal, announced November 9, 2026, adds Exton, Pennsylvania testing sites and could carry up to $75 million more in performance-based payments.
SEC filing
The contract research firm reported 4.7% organic revenue growth in the quarter ended September 26, 2026, and lifted its full-year revenue and earnings outlook.
SEC filing